NASDAQ:TLIS Talis Biomedical (TLIS) Stock Price, News & Analysis $1.75 +0.34 (+24.11%) As of 06/18/2025 01:31 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Talis Biomedical Stock (NASDAQ:TLIS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Talis Biomedical alerts:Sign Up Key Stats Today's Range$1.75▼$1.7550-Day Range$1.40▼$1.7552-Week Range$1.04▼$9.35Volume7,007 shsAverage Volume2,805 shsMarket Capitalization$3.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTalis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.Read More… Receive TLIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Talis Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address TLIS Stock News HeadlinesBaker Bros. Advisors LP's Strategic Acquisition in Talis Biomedical CorpOctober 11, 2024 | finance.yahoo.comTalis Biomedical Corp Ordinary SharesSeptember 17, 2024 | morningstar.comThis Bitcoin bull run is different…Bitcoin is back at new all-time highs. But this isn’t just a retail frenzy. This rally is being driven by huge institutional money, not just hype. Which is why smart traders are already positioning themselves for the real money… Not only from Bitcoin rising… But from the volatility that comes with it.June 20, 2025 | Brownstone Research (Ad)Talis Biomedical Shares Fall on Bankruptcy Filing, Delisting NoticeAugust 24, 2024 | marketwatch.comTLIS Stock Earnings: Talis Biomedical Reported Results for Q2 2024August 20, 2024 | investorplace.comTalis Biomedical Shares Tumble Premarket as Company Mulls BankruptcyAugust 7, 2024 | marketwatch.comWhy Talis Biomedical (TLIS) Stock Is Getting Obliterated TodayAugust 7, 2024 | benzinga.comWhy Is Talis Biomedical (TLIS) Stock Down 52% Today?August 7, 2024 | investorplace.comSee More Headlines TLIS Stock Analysis - Frequently Asked Questions How have TLIS shares performed this year? Talis Biomedical's stock was trading at $1.7590 at the beginning of the year. Since then, TLIS shares have decreased by 0.5% and is now trading at $1.75. View the best growth stocks for 2025 here. How were Talis Biomedical's earnings last quarter? Talis Biomedical Co. (NASDAQ:TLIS) released its quarterly earnings results on Tuesday, March, 15th. The company reported ($18.90) earnings per share for the quarter, topping the consensus estimate of ($19.20) by $0.30. When did Talis Biomedical's stock split? Talis Biomedical shares reverse split before market open on Thursday, July 6th 2023. The 1-15 reverse split was announced on Thursday, July 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Talis Biomedical IPO? Talis Biomedical (TLIS) raised $150 million in an initial public offering on Friday, February 12th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Piper Sandler acted as the underwriters for the IPO and BTIG was co-manager. How do I buy shares of Talis Biomedical? Shares of TLIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Talis Biomedical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Talis Biomedical investors own include Bloom Energy (BE), SoFi Technologies (SOFI), Athenex (ATNX), Alkaline Water (WTER), Milestone Scientific (MLSS), TherapeuticsMD (TXMD) and Affirm (AFRM). Company Calendar Last Earnings3/15/2022Today6/19/2025Next Earnings (Estimated)8/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:TLIS CIK1584751 Webtalis.bio Phone650-433-3000FaxN/AEmployees260Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($28.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$62.01 million Net MarginsN/A Pretax Margin-12,506.37% Return on Equity-79.74% Return on Assets-57.16% Debt Debt-to-Equity RatioN/A Current Ratio7.76 Quick Ratio7.76 Sales & Book Value Annual Sales$300 thousand Price / Sales10.63 Cash FlowN/A Price / Cash FlowN/A Book Value$37.95 per share Price / Book0.05Miscellaneous Outstanding Shares1,823,000Free Float984,000Market Cap$3.19 million OptionableNo Data Beta1.30 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:TLIS) was last updated on 6/20/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administr...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredWar-Proof Power Why This "Weird" Government Land Auction Was No Ordinary Sale When 218,000 acres of land... smack in the m...Stansberry Research | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talis Biomedical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talis Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.